Clinical lab operator Labcorp to buy bankrupt genetic test maker Invitae for $239 mlnReuters • 04/25/24
Invitae Unveils New Research for Breast Cancer Patients with Variants of Uncertain SignificancePRNewsWire • 04/11/24
Invitae Launches Update to Invitae Generation™: Clinical Variant Modeling Improves Variant ClassificationPRNewsWire • 03/12/24
Invitae Reports Estimated Unaudited Fourth Quarter and Full Year 2023 Financial ResultsPRNewsWire • 03/06/24
Invitae Partners with BridgeBio Pharma to Harness Genetic Insights for the Discovery of Rare Disease TherapeuticsPRNewsWire • 01/30/24
Despite Fast-paced Momentum, Invitae (NVTA) Is Still a Bargain StockZacks Investment Research • 12/22/23